Clinical potential of yi-gan san (yokukansan) for the treatment of psychiatric disorders

Current Psychiatry Reviews

Volumn 5, Issue 4, 2009, Pages 271-275

  Miyaoka, Tsuyoshi ^a   Horiguchi, Jun ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HERBACEOUS AGENT; UNCLASSIFIED DRUG; YI GAN SAN;

ADD ON THERAPY; BORDERLINE STATE; CELL VIABILITY; CLINICAL TRIAL; DEMENTIA; DOPAMINE RELEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HERBAL MEDICINE; HUMAN; JAPANESE; LIFE EXPECTANCY; MENTAL DISEASE; NEUROPROTECTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 70449555952     PISSN: 15734005     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340009789542114     Document Type: Review

References (29)

1. Iwasaki K, Satoh-Nakagawa T, Maruyama M. A randomized observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry 2005; 66: 248-252 (Pubitemid 40314333)
2. Jeste DV, Caligiuri MP, Paulsen JS. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995; 42: 756-765
3. Aizawa R, Kanbayashi T, Saito Y, et al. Effects of yoku-kan-sanka-chipi- hange on the sleep of normal healthy adult subjects. Psychiatry Clin Neurosci 2002; 56: 303-304 (Pubitemid 34754891)
4. Miyaoka T, Furuya M, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Yi-gan san for treatment of borderline personality disorder: an open-label study. Prog Neuropsychopharm Biol Psychiatry 2008; 32: 150-154 (Pubitemid 351312377)
5. Miyaoka T, Furuya M, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Yi-gan san for treatment of neuroleptic-induced tardive dyskinesia: : an open-label study. Prog Neuropsychopharm Biol Psychiatry 2008; 32: 761-764 (Pubitemid 351312377)
6. Miyaoka T, Furuya M, Yasuda H, Hayashida M, Nishida A, Inagaki T, Horiguchi J. Yi-gan san as adjunctive therapy for treatment-resistant schizophrenia: an open-label study. Clin Neuropharmacol 2009; 32: 6-9.
7. Tateno M, Ukai W, Ono T, Saito S, Hashimoto E, Saito T. Neuroprotective effects of Yi-Gan San against beta amyloid-induced cytotoxicity on rat cortical neurons. Prog Neuropsychopharm Biol Psychiatry 2008; 32: 1704-1707
8. Linehan MM, Tutek DA, Heard HL, Armstrong HE. Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. Am J Psychiatry 1994; 151: 1771-1776
9. Overall JE, Gorham DR . The Brief Psychiatric Rating Scale. Psychol Rep 1962; 32: 50-55
10. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1978; 133: 429-435
11. Buss AH, Perry M. The Aggression Questionnaire. J Pers Soc Psychol 1992; 63: 452-459
12. Endicott J, Spitzer R, Fleiss J. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33: 766-771
13. Guy, W (1976). ECDEU Assessment Manual for Psychopharmacogy-Revised, Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 234-537.
14. Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988; 8: 21S-26S. (Pubitemid 18214341)
15. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull 1997; 23: 583-609.
16. Seibyl JP, Glazer WM, Innis PB. Serotonin function in tardive dyskinesia. Psychiatr Ann 1989; 19: 310-314
17. Goldman D. Treatment of phenothiazine-induced dyskinesia. Psychopharmacol Bull 1976; 12: 7-10.
18. Guy W. ECDEU Assessment Manual for Psychopharmacogy-Revised, Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs 1976; 534-537 .
19. Conley RR, RV Buchanan. Evaluation of treatment-resistant schizophrenia. Schizophr Bull 1997; 23: 663-674
20. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276 (Pubitemid 18039085)
21. Inada T, Yagi G, Gardos G. Inter-rater reliability of the druginduced extrapyramidal symptoms scale (DIEPSS). In abstract of the 20th Collegium International Neuropsychopharmacologium, Melborune, 23-27.
22. Shimada Y, Goto H, Itoh T. Evaluation of the protective effects of alkaloids isolated from the hooks and stems of uncaria sinesis on glutamate-induced neuronal death in cultured cerebellar granule cells from rats. J Pharm Pharmcol1999; 51: 715-722
23. Liao JF, Jan YM, Huang SY. Evaluation with receptor binding assay on the water. Proc Natl Sci Counc Repub China B 1995; 19: 151-158
24. Hansenne M, Pitchot W, Ansseau M. Serotonin, personality and borderline personality. Acta Neuropsychiatrica 2002; 14: 66-70.
25. Lieberman JA. Understanding the mechanism of action of atypical antipsychotic drug: a review of components in use and developments. Br J Psychiatry 1993; 163 (Suppl 12): 7-18.
26. Stockmeier CA, DiCarlo JJ, Zhanng Y, Thompson P, Meltzer HY. Characterization of typical and atypical antipsychotic drugs based on in-vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 1993; 266: 1374-1384 (Pubitemid 24175781)
27. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156: 286.-293 (Pubitemid 29077120)
28. Ishibashi A, Rgashira N, Mishima K, Iwasaki K, Fujiwara M. Study on the central action of Yoku-kan-san. Yakugaku Zasshi 2006; 126: sup 2, 82-84 (Abstract in English).
29. Egashra N, Iwasaki K, Ishibashi A, et al. Repeated administration of yokukansan inhibits DOI-induced head-twitch response and decrease expression of 5-HT2A receptor in prefrontal cortex. Prog Neuropsychopharm Biol Psychiatry 2008; 32: 1516-1520